VERTEX PHARMACEUTICALS

(VRTX)
  Rapport
Vertraagde tijd Nasdaq  -  22:00 05-08-2022
288.03 USD   +4.80%
05/08VERTEX PHARMACEUTICALS : Goldman Sachs herhaalt koopadvies voor het aandeel
MM
05/08VERTEX PHARMACEUTICALS : HC Wainwright geeft koopadvies
MM
05/08VERTEX PHARMACEUTICALS : Een koopadvies van Barclays
MM
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciënConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiële publicatiesSectornieuwsAnalyse MarketScreener
Communiqués de presse de la société VERTEX PHARMACEUTICALS
05/08VERTEX PHARMACEUTICALS INC / MA Management's Discussion and Analysis of Financial Cond..
AQ
04/08VERTEX PHARMACEUTICALS : Reports Second Quarter 2022 Financial Results - Form 8-K
PU
04/08VERTEX : Q2 Earnings Snapshot
AQ
04/08Vertex Reports Second Quarter 2022 Financial Results
BU
25/07Vertex Advances VX-548 in Acute and Neuropathic Pain
AQ
22/07Vertex Advances VX-548 in Acute and Neuropathic Pain
BU
20/07Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Viv..
AQ
18/07Vertex to Announce Second Quarter 2022 Financial Results on August 4
BU
11/07VERTEX PHARMACEUTICALS : to Acquire ViaCyte, With the Goal of Accelerating its Potentially..
PU
11/07VERTEX PHARMACEUTICALS INC / MA : Other Events, Financial Statements and Exhibits (form 8-..
AQ
11/07Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-88..
BU
07/07Vertex Announces Letter of Intent With the pan-Canadian Pharmaceutical Alliance for Pub..
AQ
07/07Teva appoints Eric Hughes as head of R&D and Chief Medical Officer
AQ
07/07DBRS Morningstar Confirms All Ratings on Citigroup Commercial Mortgage Trust 2016-C2
AQ
06/07Vertex Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 C..
AQ
05/07VERTEX PHARMACEUTICALS INC / MA : Entry into a Material Definitive Agreement, Termination ..
AQ
05/07Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial fo..
BU
04/07Teva Announces Appointment of New Global R&D and Chief Medical Officer
AQ
13/06Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up ..
AQ
11/06Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up ..
BU
10/06Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatm..
BU
08/06 Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 1..
BU
08/06Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FD..
BU
06/06Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes ..
BU
02/06Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001..
BU
31/05Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Associati..
BU
23/05VERTEX PHARMACEUTICALS INC / MA : Other Events (form 8-K)
AQ
23/05Catalyst Biosciences Sells Complement Portfolio for $60 Million
AQ
19/05Vertex Pharmaceuticals - Suketu Upadhyay Elected to Vertex Board of Directors
AQ
18/05VERTEX PHARMACEUTICALS INC / MA : Submission of Matters to a Vote of Security Holders (for..
AQ
18/05Suketu Upadhyay Elected to Vertex Board of Directors
BU
17/05Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey L..
BU
17/05Vertex Announces $50 Million Commitment to Health Equity With Three Initial Grants
BU
06/05VERTEX PHARMACEUTICALS INC / MA Management's Discussion and Analysis of Financial Cond..
AQ
05/05VERTEX : Q1 Earnings Snapshot
AQ
05/05Vertex Reports First Quarter 2022 Financial Results
BU
02/05Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type..
BU
21/04Vertex to Announce First Quarter 2022 Financial Results on May 5
BU
21/04VRTX - Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor/tezacafto..
AQ
20/04Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivac..
BU
31/03Vertex Announces Statistically Significant and Clinically Meaningful Results From Two P..
BU
28/03Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA for Patients With Cy..
AQ
26/03Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA® (elexacaftor/tezaca..
BU
25/03Health Canada Grants Marketing Authorization for KALYDECO® (ivacaftor) for Patients Wit..
AQ
22/03Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated..
BU
02/03Vertex to Present at Cowen's 42nd Annual Health Care Conference on March 8
AQ
01/03Vertex to Present at Cowen's 42nd Annual Health Care Conference on March 8
BU
09/02VERTEX PHARMACEUTICALS INC / MA MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
AQ
26/01VERTEX PHARMACEUTICALS : Q4 2021 Presentation
PU
26/01VERTEX PHARMACEUTICALS : Reports Fourth Quarter 2021 and Full Year Financial Results - For..
PU
26/01VERTEX : Q4 Earnings Snapshot
AQ
26/01Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
BU
18/01Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
BU
12/01Vertex Pharmaceuticals - European Commission Approves KAFTRIO (ivacaftor/tezacaftor/ele..
AQ
11/01European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination..
BU
04/01Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10
BU
2021Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal ..
BU
2021Vertex Announces Reimbursement Agreement in Spain for KAFTRIO (ivacaftor/tezacaftor/ele..
AQ
2021Vertex Announces Reimbursement Agreement in Spain for KAFTRIO® (ivacaftor/tezacaftor/el..
BU
2021Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) i..
BU
2021VERTEX PHARMACEUTICALS INC / MA Management's Discussion and Analysis of Financial Cond..
AQ
2021Q3 2021 Presentation
PU
2021VERTEX : Q3 Earnings Snapshot
AQ
2021Broad pipeline advancing with recent progress marked by unprecedented VX-880 clinical r..
PU
2021Vertex Reports Third-Quarter 2021 Financial Results
BU
2021Vertex's Supplement to a New Drug Submission for TRIKAFTA® (elexacaftor/tezacaftor/ivac..
AQ
2021Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing T..
BU
2021VERTEX PHARMACEUTICALS : to Announce Third-Quarter 2021 Financial Results on November 2
AQ
2021VERTEX PHARMACEUTICALS : to Announce Third-Quarter 2021 Financial Results on November 2
BU
2021VERTEX PHARMACEUTICALS : to Present Long-Term Data Demonstrating Significant Benefits of T..
BU
2021VERTEX PHARMACEUTICALS : Announces Positive Day 90 Data for the First Patient in the Phase..
BU
2021VERTEX PHARMACEUTICALS : Supplement to a New Drug Submission for KALYDECO® (ivacaftor) for..
AQ
2021VERTEX PHARMACEUTICALS : Announces Letter of Intent With pan-Canadian Pharmaceutical Allia..
AQ
2021VERTEX PHARMACEUTICALS : to Present at the Morgan Stanley Virtual 19th Annual Global Healt..
AQ
2021VERTEX PHARMACEUTICALS : to Present at the Morgan Stanley Virtual 19th Annual Global Healt..
BU
1  2  3  4  5  6  7  8  9Volgende
Volgende evenement op VERTEX PHARMACEUTICALS